Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Molecular Profiling of Aggressive Non-Hodgkin Lymphoma - Results from a Phase 1/2 Preben Study

Suvi-Katri Leivonen, PhD, Judit Jørgensen, MD PhD, Thomas Stauffer Larsen, MD PhD, Annika Pasanen, MD PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Helle M Toldbod, PhD, Francesco d'Amore, MD PhD, Sirpa Leppa, MD PhD

Blood (2019) 134 (Supplement_1): 5314.

https://doi.org/10.1182/blood-2019-129113

Published: 2019

Journal Articles

Clonal Evolution of a Mutation in PTPRA As a Potential Cause for Resistance Against Anti-CD19 Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy with CTL019 in DLBCL Patients

Hyatt Balke-Want, MD, Philipp Gödel, MD, Nima Abedpour, PhD, Martin Peifer, PhD, Peter Borchmann, MD

Blood (2018) 132 (Supplement 1): 4119.

https://doi.org/10.1182/blood-2018-99-110600

Published: 2018

Journal Articles

The Burden of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Systematic Literature Review (SLR)

Georg Lenz, Sarah C. Rutherford, Andrew Davies, Pier Luigi Zinzani, MD, Gilles Salles, MD PhD, Jens Hasskarl, Sandra Margunato-Debay, Filipe Rodrigues, Lisette Nientker, Janita Balradj, Cathelijne Alleman

Blood (2018) 132 (Supplement 1): 2241.

https://doi.org/10.1182/blood-2018-99-112878

Published: 2018

Journal Articles

Ritumixab in Combination with Adapted-Dose of Ifosfamide and Etoposide As Salvage Treatment in Elderly Refractory/Relapsed Diffuse Large B-Cell Lymphoma Patients Non-Candidate for High Dose Therapy: A Retrospective Study of Lyon Hospital University

Guillaume Aussedat, Delphine Maucort-Boulch, MD PhD, Philippe Rey, MD, Violaine Safar, MD, Lionel Karlin, MD, Mad-Helenie Elsensohn, Msc, Laure Lebras, MD, Clementine Sarkozy, MD, Emmanuel Bachy, MD PhD, Bertrand Favier, PharmD, PhD, Nicolas Vantard, PharmD, Pierre Sesques, MD, Anne Lazareth, MD, Emmanuelle Ferrant, MD, Dana Ghergus, MD, Gilles Salles, MD PhD, Emmanuelle Nicolas-Virelizier, MD, Herve Ghesquieres, MD PhD

Blood (2018) 132 (Supplement 1): 4215.

https://doi.org/10.1182/blood-2018-99-116734

Published: 2018

Journal Articles

Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation

Gilles Andre Salles, Wojciech Jurczak, David J. Andorsky, MD, Donald P. Quick, MD, Jack W. Singer, MD, Simran Bedi Singh, Lixia Wang, PhD, Anton Egorov, MD, Christine Gabarroca, MSc, Ruth Pettengell, MD

Blood (2018) 132 (Supplement 1): 4189.

https://doi.org/10.1182/blood-2018-99-112455

Published: 2018

Journal Articles

Evaluation of the Effectiveness and Safety of Pixantrone for the Treatment of Multiply Relapsed or Refractory Aggressive Non Hodgkin B-Cell Lymphoma in an Ongoing International Registry

Pier Luigi Zinzani, MD PhD, Belén Navarro, MD, Juan-Manuel Sancho, MD PhD, Begoña Soler, MD, Silvina Grasso Cicala, PhD, Lorena Yapur, MD, Mario Spione, PharmD, MSc

Blood (2017) 130 (Supplement 1): 5228.

https://doi.org/10.1182/blood.V130.Suppl_1.5228.5228

Published: 2017

Journal Articles

Preben: Pixantrone, Rituximab, Etoposide and Bendamustine, Spanish Experience in Diffuse Large B-Cell Lymphoma Treatment

Cristina Barrenetxea Lekue, PhD, Clara Alonso Caballero, Laura Hernández Vázquez, Belen Navarro Matilla, Fco Javier Capote Huelva, Dolores Caballero, MD PhD, Noelia Purroy Zuriguel, Irene Leal Martinez, Daniela Caballero Alvarez, Jose Antonio Marquez Navarro, Fernando Marco de Lucas

Blood (2017) 130 (Supplement 1): 5235.

https://doi.org/10.1182/blood.V130.Suppl_1.5235.5235

Published: 2017

Journal Articles

R-GCVP As Second Line Treatment in Elderly Patients with DLBCL Who Fail R-CHOP and Are Not Candidates for Intensive Therapy

Betty Gration, MBBS, Ana Duran, MD, Naheed Mir, BSc, FRCP, FRCPath, Lisa Yuen, MPharm, PgDip, IP, Marcus Warner, MPharm, PG Dip GPP, Karen Stanley, RGN, MSc Advanced Practice, Jessica Brady, MBBCh, FRCR, George Mikhaeel, MB BCh, MSc, FRCR, Paul A Fields, MD PhD, David Wrench, MA, MBBChir, FRCPath, PhD

Blood (2017) 130 (Supplement 1): 4133.

https://doi.org/10.1182/blood.V130.Suppl_1.4133.4133

Published: 2017

Journal Articles

The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)

Michael Roost Clausen, MD, Sirpa Leppa, MD, Peter de Nully Brown, MD, Jette Soenderskov Goerloev, MD, Michael Panny, MD, Wolfgang Willenbacher, MD, Ida Blok Sillesen, MD, Erik Segel, MD, Hans Bentzen, MD, Michael Thorsgaard, MD, Elisa Jacobsen Pulczynski, MD, Peter Kamper, MD, Lars C. Gormsen, MD, Julie Mortensen, MDcal Student, Grethe Lauritzsen, MD, Thomas Relander, MD PhD, Francesco d'Amore, MD PhD

Blood (2016) 128 (22): 1782.

https://doi.org/10.1182/blood.V128.22.1782.1782

Published: 2016

Journal Articles

Obinutuzumab (GA101) in Combination with Pixantrone for the Treatment of Patients with Relapsed Aggressive B-Cell Lymphoma: Report on an Ongoing Phase II Trial (GOAL)

Georg Hess, MD, Andreas Hüttmann, MD, Reinhard Marks, MD, Mathias Witzens-Harig, MD, Martin H. Dreyling, MD PhD, Andreas Viardot, Georg Lenz, MD, Christiane Pott, Annegret Kuhn, MD, Christian Ruckes, Matthias Theobald, MD, Ulrich Keller

Blood (2016) 128 (22): 5392.

https://doi.org/10.1182/blood.V128.22.5392.5392

Published: 2016

Journal Articles

Endpoints of Clinical Trials for Marketing Authorization of Drugs for Hematologic Malignancy in Japan, the US and the EU

Sumimasa Nagai, MD, PhD

Blood (2014) 124 (21): 2603.

https://doi.org/10.1182/blood.V124.21.2603.2603

Published: 2014

Journal Articles

Preliminary Clinical Experience on the Efficacy and Feasibility of a New Combination Regimen Consisting of Pixantrone, Etoposide, and Bendamustine with or without the Addition of Rituximab in Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphomas

Francesco d'Amore, Judit Joergensen, Ida Blok Sillesen, Erik Segel, Hans Bentzen, Michael Thorsgaard, Elisa Jacobsen Pulczynski, Bjarne Bach Pedersen, Dorte Gillström, Michael Clausen, Peter Kamper, Trine Silkjaer, Lars C. Gormsen, Sirpa Leppä, Helle Toldbod

Blood (2014) 124 (21): 5435.

https://doi.org/10.1182/blood.V124.21.5435.5435

Published: 2014

Journal Articles

In-Vitro Actvity of Pixantrone (PIX) in Plasma Cell Leukaemia (PCL) and Early Clinical Activity in a Pixantrone–Pomalidomide–Dexamethasone (PiPoD) Combination

Ella Willenbacher, MD, Wolfgang Willenbacher, MD, Gunther Gastl, Prof., Dr., Irmgard Verdorfer, MDPhD, Brigitte Kircher, PhD

Blood (2014) 124 (21): 5732.

https://doi.org/10.1182/blood.V124.21.5732.5732

Published: 2014

Journal Articles

Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment

Emanuela Salvatorelli, MD, Odalys Gonzalez Paz, PhD, Elvio Covino, MD, Massimo Chello, MD, Jack Singer, MD, Pierantonio Menna, PhD, Giorgio Minotti, MD

Blood (2011) 118 (21): 4966.

https://doi.org/10.1182/blood.V118.21.4966.4966

Published: 2011

Journal Articles

CPOP-R Versus CHOP-R As First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-Label, Multicenter Study

Raoul Herbrecht, David MacDonald, MD, FRCPC, Florian Weissinger, MD, Martin Wilhelm, MD, Charles Holladay, MS, MD, Nam H. Dang, MD, PhD, Peter Holman, MD, Paul Cernohous, MS, Jack Singer, MD, Richard H. van der Jagt, MD, FRCPC

Blood (2011) 118 (21): 1605.

https://doi.org/10.1182/blood.V118.21.1605.1605

Published: 2011

Journal Articles

Pixantrone Dimaleate (PIX) and Comparators In the Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (aNHL): An Analysis of Response and Survival by Gender and Age

Jack Singer, MD, Paul Cernohous, MS, Gabor Jurida, MD, Lixia Wang, PhD, Christine Kuepfer, MS, Ruth Pettengell, FRACP, PhD

Blood (2010) 116 (21): 4883.

https://doi.org/10.1182/blood.V116.21.4883.4883

Published: 2010

Journal Articles

Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.

Ruth Pettengell, FRACP, PhD, Pier Luigi Zinzani, MD, PhD, Geetha Narayanan, MD, Fernando Hurtado de Mendoza, MD, Raghunadharao Digumarti, MD, Henry Gomez, MD, Bertrand Coiffier, MD, PhD, Gary Schiller, MD, David A. Rizzieri, MD, Paul Cernohous, MS, Lixia Wang, PhD, Jack Singer, MD

Blood (2010) 116 (21): 2833.

https://doi.org/10.1182/blood.V116.21.2833.2833

Published: 2010

Journal Articles

LACK of IRON Binding by Pixantrone IS ASSOCIATED with Reduced PRODUCTION of Reactive Oxygen SPECIES and Myoctye Cytotoxicity IN VITRO.

Miles Hacker, Ph.D., Marc McKennon, Ph.D., Jack W. Singer, MD

Blood (2009) 114 (22): 4806.

https://doi.org/10.1182/blood.V114.22.4806.4806

Published: 2009

Journal Articles

Phase III Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin's Lymphoma (EXTEND): Results From the Treatment and Follow-up Periods.

Ruth Pettengell, MD, Bertrand Coiffier, MD, Geetha Narayanan, MD, Fernando Hurtado de Mendoza, MD, Raghunadharao Digumarti, MD, Henry Gomez, MD, Pier Luigi Zinzani, MD, Gary J Schiller, MD, David A Rizzieri, MD, Paul Cernohous, Lixia Wang, Jack W. Singer, MD

Blood (2009) 114 (22): 1677.

https://doi.org/10.1182/blood.V114.22.1677.1677

Published: 2009

Journal Articles

CHOP-R (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab) Compared to CPOP-R (Cyclophosphamide, Pixantrone, Vincristine, Prednisone, Rituxamib) in First-Line Therapy of Diffuse Large B Cell Lymphoma (DLBCL): An Interim Analysis.

Raoul Herbrecht, MD, Stephen Couban, MD, Florian Weissinger, MD, Igor Gorbatchevsky, MD, Richard H. van der Jagt, MD

Blood (2007) 110 (11): 3445.

https://doi.org/10.1182/blood.V110.11.3445.3445

Published: 2007

NARROW

Molecular Profiling of Aggressive Non-Hodgkin Lymphoma - Results from a Phase 1/2 Preben Study

Clonal Evolution of a Mutation in PTPRA As a Potential Cause for Resistance Against Anti-CD19 Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy with CTL019 in DLBCL Patients

The Burden of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Systematic Literature Review (SLR)

Ritumixab in Combination with Adapted-Dose of Ifosfamide and Etoposide As Salvage Treatment in Elderly Refractory/Relapsed Diffuse Large B-Cell Lymphoma Patients Non-Candidate for High Dose Therapy: A Retrospective Study of Lyon Hospital University

Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation

Evaluation of the Effectiveness and Safety of Pixantrone for the Treatment of Multiply Relapsed or Refractory Aggressive Non Hodgkin B-Cell Lymphoma in an Ongoing International Registry

Preben: Pixantrone, Rituximab, Etoposide and Bendamustine, Spanish Experience in Diffuse Large B-Cell Lymphoma Treatment

R-GCVP As Second Line Treatment in Elderly Patients with DLBCL Who Fail R-CHOP and Are Not Candidates for Intensive Therapy

The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)

Obinutuzumab (GA101) in Combination with Pixantrone for the Treatment of Patients with Relapsed Aggressive B-Cell Lymphoma: Report on an Ongoing Phase II Trial (GOAL)

Endpoints of Clinical Trials for Marketing Authorization of Drugs for Hematologic Malignancy in Japan, the US and the EU

Preliminary Clinical Experience on the Efficacy and Feasibility of a New Combination Regimen Consisting of Pixantrone, Etoposide, and Bendamustine with or without the Addition of Rituximab in Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphomas

In-Vitro Actvity of Pixantrone (PIX) in Plasma Cell Leukaemia (PCL) and Early Clinical Activity in a Pixantrone–Pomalidomide–Dexamethasone (PiPoD) Combination

Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment

CPOP-R Versus CHOP-R As First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-Label, Multicenter Study

Pixantrone Dimaleate (PIX) and Comparators In the Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (aNHL): An Analysis of Response and Survival by Gender and Age

Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.

LACK of IRON Binding by Pixantrone IS ASSOCIATED with Reduced PRODUCTION of Reactive Oxygen SPECIES and Myoctye Cytotoxicity IN VITRO.

Phase III Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin's Lymphoma (EXTEND): Results From the Treatment and Follow-up Periods.

CHOP-R (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab) Compared to CPOP-R (Cyclophosphamide, Pixantrone, Vincristine, Prednisone, Rituxamib) in First-Line Therapy of Diffuse Large B Cell Lymphoma (DLBCL): An Interim Analysis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only